Trial Profile

A Phase I Trial to Evaluate Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Gamma delta T Cells (CTM-N2D) in Subjects With Advanced Solid Tumours or Haematological Malignancies (the ANGELICA Trial)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-NKG2DL gamma delta CAR-T cell therapy-Cytomed Therapeutics (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2; Zoledronic acid
Indications Colorectal cancer; Haematological malignancies; Liver cancer; Lung cancer; Lymphoma; Multiple myeloma; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms ANGELICA
Sponsors CytoMed Therapeutics

28 Apr 2025 According to a CytoMed Therapeutics media release, initial clinical readout from this trial anticipated by end of 2025.
22 Nov 2024 Planned number of patients changed from 9 to 12.
22 Nov 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com